Britt Erickson, MD
Gynecologic Oncology · Minneapolis, MNNPI 1225294762
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $25,912 of the $28,016 with a category attached, or 92.5%. 10 manufacturers reported payments, led by GSK at 29.3% of the total. Reporting peaked in 2024 at $11,852 and has fallen 89.4% since, to $1,253 in 2025.
Across 25 payments — averaging $1120.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$8K
- AstraZeneca$7K
- Merck$5K
- Boston Scientific$4K
- AbbVie$2K
- Eli Lilly$1K
- plus $442 from 4 others
Across 5 payments — averaging $175,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$879K
What the payments were for
- Consulting fees$25,91292%
- Grants$1,3485%
- Food & beverage$7573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 4 | $8,200 |
| AstraZeneca | 7 | $6,526 |
| Merck | 3 | $5,185 |
| Boston Scientific | 3 | $4,142 |
| AbbVie | 2 | $2,269 |
| Eli Lilly | 2 | $1,253 |
| Covidien LP | 1 | $360 |
| Eisai Inc. | 1 | $36 |
| Intuitive Surgical | 1 | $29 |
| Clovis Oncology, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JEMPERLI$8,200
- GENERAL HYSTEROSCOPIC BIOPSY$3,867
- GENERAL - THERAPIES$275
How this compares
$28,016 in reported general payments places this provider in the 85th percentile of 39 gynecologic oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 11 | $535 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Minneapolis
- Melissa GellerMinneapolis$14K
- Emily PrendergastMinneapolis$10K
- Colleen Rivard HuntMinneapolis$3K
- Sabrina BedellMinneapolis$1K
- Jordan MattsonMinneapolis$1K
- Lauren BollingerMinneapolis$355
- Deanna TeohMinneapolis$135
- Alexandra SchefterMinneapolis$77
- Sally MullanyMinneapolis$47
- Rahel GhebreMinneapolis$15
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.